Tenderwize
Wróć do wyszukiwania

Open House Original Discount Contracts 2025-27 - Ribociclib

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2027 · 431 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-27 - Ribociclib

70/100

Ocena szansy

PromisingLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

70 / 100

Złożoność

20 / 100

Czynniki ryzyka

Contract ends automatically at the end of the month in which the patent or market exclusivity for Ribociclib expires. T...

No estimated value or volume is provided; revenue is uncertain and depends on actual prescriptions.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Conclude discount contracts for the active ingredient Ribociclib with eligible pharmaceutical entrepreneurs.
  • Ensure pharmacy software update for new discount products by submitting documents before the 3rd of the preceding month.
Pokaż pełne podsumowanie

Open House procedure by Techniker Krankenkasse (TK) to conclude discount contracts (Rabattverträge) for the active ingredient Ribociclib under §130c SGB V. The process is non-competitive: any eligible pharmaceutical entrepreneur that meets the criteria (valid marketing authorization, being a pharmaceutical entrepreneur within EU/EEA) can join at any time during the contract duration (01.11.2025 – 31.10.2027). No exclusivity is granted. The notice clarifies this is not a public procurement under EU directives; legal recourse is to social courts. No estimated value is provided. Contract termination occurs automatically upon patent expiry. Documents are available online but submission is via email or post (not electronic via the platform).

Ryzyka

Contract ends automatically at the end of the month in which the patent or market exclusivity for Ribociclib expires. T...

No estimated value or volume is provided; revenue is uncertain and depends on actual prescriptions.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Be a pharmaceutical entrepreneur within the meaning of §4(18) AMG, with a valid marketing authorization (or equivalent right) for Ribociclib.

Eligibility

  • No exclusion grounds analogous to §§123, 124 GWB for the last 3-5 years.

Administrative

  • Submit signed contract documents (including self-declaration on authorization and company – Anlage 4) via email with qualified electronic signature or by post.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Original Discount Contracts 2025-27 - Ribociclib

Conclusion of discount contracts for the active ingredient Ribociclib with eligible pharmaceutical entrepreneurs. The contract has a maximum duration of 24 months starting 01.11.2025, ending no later than 31.10.2027. Early termination upon patent expiry.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Oct 2025 - Oct 2027

Kategoria

Pharmaceutical products

Szczegóły zamówienia

Data publikacji
17 Sep 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
612458-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3